(Bold for FDA approved)
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibits neuronal activity presumably in amygdala-centered fear circuits to provide therapeutic benefits in anxiety disorders
• Some immediate relief with first dosing is common; can take several weeks with daily dosing for maximal therapeutic benefit
• Sedation, fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
unusual
common
• Wait
• Wait
• Wait
• Lower the dose
• Take largest dose at bedtime to avoid sedative effects during the day
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
• Mild to moderate anxiety: 15–40 mg/day in 3–4 doses
• Severe anxiety: 60–100 mg/day in 3–4 doses
• Capsule 2.5 mg, 5 mg, 10 mg, 25 mg
• Evidence of efficacy for up to 16 weeks
• Risk of dependence, particularly for treatment periods longer than 12 weeks, and especially in patients with past or current polysubstance abuse
• Chlordiazepoxide is a Schedule IV drug
• Patients may develop dependence and/or tolerance with long-term use
• Initial 10–20 mg/day in 2–4 doses; increase as needed
• Initial 10–20 mg/day in 2–4 doses; increase as needed
• Benzodiazepines have been used to treat anxiety associated with acute myocardial infarction
• Initial 10–20 mg/day in 2–4 doses; increase as needed
• Elderly patients may be more sensitive to sedative effects
• Not recommended for use in children under age 6
• Initial 10–20 mg/day in 2–4 doses; may increase to 20–30 mg/day in 2–3 doses if ineffective
• Hyperactive children should be monitored for paradoxical effects
• Long-term effects of chlordiazepoxide in children/adolescents are unknown
• Should generally receive lower doses and be more closely monitored
• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Possible increased risk of birth defects when benzodiazepines are taken during pregnancy
• Because of the potential risks, chlordiazepoxide is not generally recommended as treatment for anxiety during pregnancy, especially during first trimester
• Drug should be tapered if discontinued
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Seizures, even mild seizures, may cause harm to the embryo/fetus
Unknown if chlordiazepoxide is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
• Effects of benzodiazepines on nursing infants have been reported and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera